Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated mortality worldwide with an overall five-year survival rate less than 7%. Accumulating evidence has revealed the cancer preventive and therapeutic effects of metformin, one of the most widely prescri...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ke, Qian, Weikun, Jiang, Zhengdong, Cheng, Liang, Li, Jie, Sun, Liankang, Zhou, Cancan, Gao, Luping, Lei, Meng, Yan, Bin, Cao, Junyu, Duan, Wanxing, Ma, Qingyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525317/
https://www.ncbi.nlm.nih.gov/pubmed/28738823
http://dx.doi.org/10.1186/s12943-017-0701-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525317/
https://www.ncbi.nlm.nih.gov/pubmed/28738823
http://dx.doi.org/10.1186/s12943-017-0701-0

Ejemplares similares